Trials / No Longer Available
No Longer AvailableNCT03717181
Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
Expanded Access Use of Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Palladio Biosciences · Industry
- Sex
- All
- Age
- 15 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD) related to the cystic expansion. This study will investigate whether the vasopressin V2 receptor antagonist lixivaptan can alleviate intractable pain in a pediatric PKD patient who cannot tolerate the related vasopressin V2 receptor antagonist tolvaptan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lixivaptan | Daily dose of lixivaptan optimized using a predetermined titration protocol. |
Timeline
- First posted
- 2018-10-24
- Last updated
- 2021-10-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03717181. Inclusion in this directory is not an endorsement.